Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Citius Oncology, Inc.NASDAQ: CTOR
Property, Plant & Equipment (Net) · Q2 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) remains negative
Q2 FY2026 property, plant & equipment (net) was $0, compared with $0 a year earlier.
Context
- Property, plant & equipment (net) amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Property, plant & equipment (net) increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 0 | — |
| FY2024 | 2024-09-30 | 0 | — |
| FY2023 | 2023-09-30 | 0 | — |
| FY2022 | 2022-09-30 | 0 | — |
Property, Plant & Equipment (Net) vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's Mar 2026 property, plant & equipment (net) of $0 is the 9th highest of the 10 companies compared; the peer median is $3.39M.
- Property, plant & equipment (net) amounts to 0.0% of total assets for CTOR, versus a peer median of 2.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $95.34M | -11.7% | +14.3% | 33.5% | |
| Mar 2026 | $77.08M | -13.8% | -15.7% | 65.5% | |
| Mar 2026 | $27.55M | +899.8% | +146.3% | 9.4% | |
| Mar 2026 | $15.65M | +8.1% | -58.1% | 23.6% | |
| Mar 2026 | $3.39M | -91.5% | -60.7% | 0.7% | |
| Mar 2026 | $1.26M | -55.8% | -35.4% | 2.1% | |
| Mar 2026 | $720K | +246.2% | -50.8% | 0.8% | |
| Mar 2026 | $110K | -12.0% | — | 0.2% | |
CTORCitius Oncology, Inc. | Mar 2026 | $0 | — | — | 0.0% |
ACTUActuate Therapeutics Inc | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding CTOR) | $3.39M | -11.8% | -35.4% | 2.1% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.